Skip to main content
Legislative TrackerBillsFederal
119
S 3314

Federal Bill: S 3314

Written Informed Consent Act

Topics

Health Freedom
Mental Health

Bill Information

MAHA Approved

Summary

Bill Summary

US S 3314, the Written Informed Consent Act, directs the Secretary of Veterans Affairs to expand an existing Veterans Health Administration directive on written informed consent for long‑term opioid therapy so that it also covers a broader set of high‑risk psychiatric and pain medications. Specifically, the bill orders VA to update VHA Directive 1005 (“Informed Consent for Long‑Term Opioid Therapy for Pain”) so that written, signed informed consent is required before prescribing antipsychotics, stimulants, antidepressants, anxiolytics (anti‑anxiety drugs), and narcotics, not just long‑term opioids. For these drug classes, VA clinicians would have to provide veterans with clear written information about intended effects, major risks (including black‑box warnings), side effects, and alternatives, and obtain a signed consent form stating that the veteran has been informed before initiating treatment. The bill does not restrict clinical judgment on whether to prescribe, but standardizes and documents the consent process across these high‑risk medications within VA.


Why It Matters to MAHA

The Make America Healthy Again Movement supports S 3314 because it strengthens transparency and informed choice around potent psychiatric and pain medications, which aligns with MAHA’s emphasis on fully informing patients about risks and alternatives—including nutrition, movement, and other non‑drug strategies—before long‑term pharmaceutical treatment. Veterans often receive multiple prescriptions, including psychotropics and narcotics, and have raised concerns about overprescription and side effects; requiring written informed consent helps slow down automatic prescribing and encourages more thorough conversations about benefits, harms, and options. By making VA explain and document the risks of antipsychotics, antidepressants, stimulants, anxiolytics, and narcotics up front, the bill supports MAHA’s broader goal of reducing avoidable medication‑related harm while preserving access when these drugs are truly necessary.

Introduced

12/02/2025

In Committee

12/02/2025

Passed

Pending

Sponsors

Tommy Tuberville

Tommy Tuberville

Republican Senator (AL)

202-224-4124tuberville.senate.gov

Tim Sheehy

Republican Senator (MT)

202-224-2644sheehy.senate.gov

Questions or suggestions?

Have questions about this bill or our legislative tracker? We'd love to hear from you. Contact us and we'll get back to you as soon as possible.
Contact us
MAHA® Action
Legislative TrackerMedia HubMAHA WinsMAHA ReportAboutShop
Search
legislative tracker

Legislative Tracker: Track, Advocate & Influence Policy

Track billsView all bills
Featured
Other Great OrganizationsFind other great organizations working alongside us
The MAHA ReportRead the latest MAHA Report and stay informed on all things MAHA™
VolunteerVolunteer your time to help us achieve our mission
Learn More
Contact UsFAQInternshipsSpeaker SubmissionVolunteerEndorsements
Other
Submit a WinAdd OrganizationRegister to votePrivacy PolicyTerms of Service
SearchJoinSign InDonate
HomeAboutLegislative TrackerContactVolunteerInternshipsSubmit a WinAdd OrganizationDisinfo Dozen

Get in on the action

Get updates in your inbox, right as they happen. No waiting, just info right to you.

Instagram
Facebook
X
YouTube

Privacy Policy  |  Terms of Service | 

© 2026 MAHA Action. All rights reserved.

MAHA® Action

“Make America Healthy Again®”

MAHA Action exists to revive and empower a healthier America, free of corporate interests, for the health and prosperity of our communities and country.